What is SolveBio?
Founded in 2013, SolveBio addresses critical challenges in translational medicine by leveraging technology to integrate multi-omics and clinical outcomes data. The company partners with leading pharmaceutical, diagnostics, and CDx organizations to enhance therapeutic and diagnostic development. SolveBio's proprietary technology enables real-time indexing, harmonization, and linking of complex biological data, connecting external sources with internal customer information. This provides biotech, pharma, and diagnostic clients with a dynamic, collaborative view of targets, biomarkers, and clinical trials, facilitating effective molecular knowledge utilization. Based in New York, SolveBio operates within the burgeoning health-tech and bioinformatics industry, a sector characterized by rapid innovation and significant investment.
How much funding has SolveBio raised?
SolveBio has raised a total of $2M across 1 funding round:
Angel/Seed
$2M
Angel/Seed (2014): $2M with participation from Andreessen Horowitz and SV Angel
Key Investors in SolveBio
Andreessen Horowitz
Andreessen Horowitz is a prominent venture capital firm known for investing in technology companies across various stages, often focusing on disruptive innovations and market leaders.
SV Angel
SV Angel is a venture capital firm that provides early-stage funding and strategic support to technology startups, emphasizing long-term partnerships with founders.
What's next for SolveBio?
The recent major strategic investment in SolveBio signals a pivotal growth phase for the company. This capital infusion is expected to accelerate the expansion of its data integration and analysis platform, potentially enabling deeper collaborations with a wider array of life sciences organizations. SolveBio's focus on real-time, harmonized multi-omics and clinical data positions it to capitalize on the increasing demand for precision medicine solutions. Future developments may include enhanced AI-driven insights and broader market penetration within the pharmaceutical and diagnostic development landscape, solidifying its role as a key enabler of therapeutic innovation.
See full SolveBio company page
